DSM-Firmenich AG (DSFIY) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of DSM-Firmenich AG $2.45, price $10.81, upside -77.3%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DSM-Firmenich AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
31‑month range $6.19 – $12.97 · fair‑value band $1.50 – $3.46 · the $10.81 price screens above the $2.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Follow DSM-Firmenich in your weekly email
Every Wednesday you see whether DSM-Firmenich is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health.
Show more
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
Stock analysis
DSM-Firmenich AG (DSFIY) currently trades at $10.81, while our model-based Fair Value estimate is $2.45, 77.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $5.59 per share, and 2 of the 16 models we run sit above the $10.81 price.
Bear case: the Earnings-Based group reads lowest at $1.68, and 14 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: $1.50 (bear) to $3.46 (bull), the price of $10.81 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DSM-Firmenich AG reported revenue of €9.0B in FY2025 versus €11.4B in FY2021, a compound −5.7%/yr. Reported net income was −€1.1B in FY2025.
Key figures
Market cap $22.0B · P/E ratio 77.2 · P/S ratio 2.43 · EPS (TTM) $0.1400 · Net margin −12.0% · Return on equity 1.7% · Return on assets (EBIT) 1.5% · Operating margin 7.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −77%, DSFIY screens richer than that median.
Fair Value models
Bear $1.50Fair Value $2.45Bull $3.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.1% (2021) → 7.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −10.0% a year for the price and +1.4% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (49 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 696 stocks
Beats the industry median on 3/15 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−33.8% · Below median
Profitability
Return on equity (TTM)1.7% · Below median
Return on assets1.3% · Below median
Net margin (TTM)−12.0% · Bottom 25%
Operating margin (TTM)7.0% · Below median
Growth and dividend
Revenue growth3.4% · Below median
Dividend yield (TTM)23.1% · Top 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)77.2× · Priciest 25%
P/B1.19× · Cheaper than median
P/S (TTM)2.43× · Pricier than median
P/FCF33.7× · Pricier than median
EV/EBITDA16.6× · Pricier than median
PEG0.77× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)17· sector 54
PAST (return on equity)7· sector 26
HEALTH (low debt)90· sector 95
DIVIDEND (yield)100· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DSM-Firmenich AG Fair Value". https://www.fairvalue-calculator.com/stock/DSFIY
Frequently asked questions
Is DSM-Firmenich AG (DSFIY) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $2.45 versus a price of $10.81, about −77% upside (overvalued).
What is the fair value of DSFIY?
Our model-based fair value for DSM-Firmenich AG is $2.45 (as of Sep 29, 2026), built from audited fundamentals. The current price: $10.81.
What is the quality score of DSFIY?
DSM-Firmenich AG has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DSM-Firmenich AG (DSFIY)?
Our model-based price target is the fair value of $2.45 (as of Sep 29, 2026) from 16 valuation models. Cautious scenario $1.50, optimistic scenario $3.46. It is a calculation from audited fundamentals, not an analyst target.
What is the DSM-Firmenich AG stock forecast for 2026?
Our models put fair value at $2.45, about −77% upside versus a price of $10.81 (overvalued). Cautious scenario $1.50, optimistic scenario $3.46. The calculation is refreshed regularly with new filings.
What is the revenue of DSM-Firmenich AG (DSFIY)?
DSM-Firmenich AG reported trailing-twelve-month revenue of about €9.0B (latest available figure, as of Sep 29, 2026).
What growth is priced into DSM-Firmenich AG (DSFIY)?
For today's price to be fair in a discounted-cash-flow model, DSM-Firmenich AG would have to grow free cash flow by -8.1 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -5.7 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of DSFIY use?
Our models discount DSM-Firmenich AG at 8.3 %: a base by market capitalisation (large), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DSM-Firmenich AG that is -8.1 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has DSM-Firmenich AG (DSFIY) delivered so far?
Over the past 4 years revenue at DSM-Firmenich AG grew -5.7 % a year. The price currently implies -8.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DSM-Firmenich AG (DSFIY) growing?
The median revenue growth in the sector is +15.9 % a year. That is the yardstick for the growth priced into DSM-Firmenich AG (-8.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DSM-Firmenich AG (DSFIY)?
The free-cash-flow yield on the price is 26.87 %: that much free cash flow DSM-Firmenich AG produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DSM-Firmenich AG (DSFIY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DSM-Firmenich AG it is $2.45 per share (as of Sep 29, 2026), against a price of $10.81. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is DSM-Firmenich AG stock overvalued or undervalued in 2026?
As of Sep 29, 2026, DSFIY trades above its calculated fair value: price $10.81, fair value $2.45, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DSFIY?
No. The price is what the market pays today ($10.81); the fair value is what the company's own numbers justify ($2.45). For DSM-Firmenich AG the two are $8.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is DSM-Firmenich AG worth?
The market values DSM-Firmenich AG at about $22.0B (market capitalisation, as of Sep 29, 2026). Per share that is $10.81; our models calculate a fair value of $2.45 per share.
What do the bullish and bearish scenarios say about DSFIY?
Our models span a range for DSM-Firmenich AG: cautious scenario $1.50, base $2.45, optimistic $3.46 per share (as of Sep 29, 2026, price $10.81). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DSFIY?
DSM-Firmenich AG trades at a price-to-earnings ratio of 77.2 (as of Sep 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.45 is built from several models across several years. Other multiples: PEG 0.8, P/B 1.2, P/S 2.4, EV/EBITDA 16.6.
What is the PEG ratio of DSFIY?
The PEG ratio of DSM-Firmenich AG is 0.77 (P/E divided by earnings growth, as of Sep 29, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of DSM-Firmenich AG (DSFIY)?
Balance-sheet figures for DSM-Firmenich AG (as of Sep 29, 2026): return on equity 1.7%, debt of 0.20 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is DSFIY from its 52-week high?
DSM-Firmenich AG trades at $10.81, about 4% below its 52-week high of $11.24 and 75% above the low of $6.19 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.45 is for.
Which stocks are comparable to DSM-Firmenich AG?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DSM-Firmenich AG stock attractive at the current price?
The data as of Sep 29, 2026: price $10.81, calculated fair value $2.45 (−77%), Quality Score 33/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DSFIY calculated?
We run DSM-Firmenich AG through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. DSM-Firmenich AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DSM-Firmenich AG (DSFIY)?
The closing price on Oct 2, 2026 was $10.81. Our model-based fair value is $2.45, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DSM-Firmenich AG right now?
The price sits above even our optimistic bull case ($3.46). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($1.50 to $3.46) leaves room in how you read the outcome.
Key figures of DSM-Firmenich AG
How large is the market capitalisation of DSM-Firmenich AG (DSFIY)?
The market capitalisation of DSM-Firmenich AG is $22.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DSM-Firmenich AG (DSFIY)?
The price-to-sales ratio of DSM-Firmenich AG is 2.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DSM-Firmenich AG (DSFIY)?
Earnings per share at DSM-Firmenich AG are $0.1400 (price ÷ EPS = P/E 77.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DSM-Firmenich AG (DSFIY)?
The net margin of DSM-Firmenich AG is −12.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DSM-Firmenich AG (DSFIY)?
The return on equity (ROE) of DSM-Firmenich AG is 1.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DSM-Firmenich AG (DSFIY)?
On an EBIT basis the return on assets of DSM-Firmenich AG is 1.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DSM-Firmenich AG (DSFIY)?
The operating margin of DSM-Firmenich AG is 7.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DSM-Firmenich AG (DSFIY)?
Revenue at DSM-Firmenich AG is growing +3.4% versus a year earlier (3y avg +2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DSM-Firmenich AG (DSFIY)?
Earnings per share at DSM-Firmenich AG are growing +11.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DSM-Firmenich AG (DSFIY) carry?
The net debt of DSM-Firmenich AG is €3.5B (fiscal year 2025, ≈ 5.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DSM-Firmenich AG in the live analysis
One click puts DSM-Firmenich AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 29, 2026